Previous studies have shown that several protein kinase inhibitors are time-dependent inhibitors of cytochrome P450 (CYP) 3A. We screened 14 kinase inhibitors for time-dependent inhibition of CYP2C8 and CYP3A. Amodiaquine N-deethylation and midazolam 19-hydroxylation were used as marker reactions for CYP2C8 and CYP3A activity, respectively. A screening, IC50 shift, and mechanismbased inhibition...

The Rockefeller University Press $30.00 J. Cell Biol. Vol. 204 No. 7 1209–1218 www.jcb.org/cgi/doi/10.1083/jcb.201312098 JCB 1209 E.J. Hagedorn and L.C. Kelley contributed equally to this paper. Correspondence to David Sherwood: [email protected] E.J. Hagedorn’s present address is Boston Children’s Hospital, Boston, MA 02115. Abbreviations used in this paper: AC, anchor cell; ADF, actin-d...

We performed time-series photometry of the PG1159-type star HE 1429−1209, which was recently discovered in the ESO SPY survey. We show that the star is a low-amplitude (≈0.05 mag) non-radial g-mode pulsator with a period of 919 s. HE 1429−1209 is among the hottest known post-AGB stars (T eff =160 000 K) and, together with the known pulsator RX J2117.1+3412, it defines empirically the blue edge ...

References http://rspb.royalsocietypublishing.org/content/278/1709/1209.full.html#related-urls Article cited in: http://rspb.royalsocietypublishing.org/content/278/1709/1209.full.html#ref-list-1 This article cites 52 articles, 5 of which can be accessed free Subject collections (1165 articles) evolution • (1055 articles) ecology • (778 articles) behaviour • Articles on similar topics can be ...

A novel polyomavirus was identified in a fatally diseased Gouldian finch (Erythrura gouldiae). The new polyomavirus, strain VL 1209, was detected using a broad-spectrum nested PCR.

Leucht S, Barnes TRE, Kissling W, et al. Relapse prevention in schizophrenia with new generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209–22. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...